International investors including BlackRock and Fidelity are anchoring a boom in Hong Kong biotech listings, with Chinese healthcare companies raising a record $21.1bn from share offerings in the city this year.
Hong Kong is seeking to supplant New York’s Nasdaq as the world’s largest biotech fundraising centre by 2025. The rush of interest from western investors follows reforms two years ago that allowed biotech groups with no revenue to go public in the Asia finance hub for the first time.
Those listings have been backed by so-called cornerstone investors from the US and elsewhere, which in return for a large allocation agree not to sell their shares within six months following an initial public offering.
您已閱讀21%（714字），剩余79%（2728字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。